Keytruda plus MRK's momentum in hepatitis C treatment may have made the stock a bit too hot last year. This article categorizes and reviews MRK's marketed products from a patent expiration and revenue/growth perspective. Even with …
On Tuesday, Argus reiterated its “buy” rating for MRK stock, and Toung said Lynparza has sweetened the deal. Pharmaceutical giant Merck already has a major growth driver in its Keytruda cancer treatment, and Toung sees even …
Short interest has increased by 15% over the last two reporting periods, and 22% of CLNT stock's total available float is now sold short. MRK stock is down 0.8% today, trading at $63.43, after the company paused enrollment for two cancer …
Oddly, perhaps, the best performing stock in the first two weeks of the year is drug maker Merck & Co. Inc. (NYSE: MRK). The stock has added 5.89% year to date. Last Wednesday was a big day for the company, as three analysts lifted the …
Merck & Co., Inc. (MRK ) shares have fallen more than 10% since last Thursday ... but the long-term trend is likely to remain bearish barring any fundamental improvements. If the stock moves lower, the next major area of support is …
Stock futures were lower on Monday ... Akzo Nobel Confirms $30 Billion Merger …
Merck’s MRK Keytruda has hit a stumbling block with the FDA placing three combination studies on clinical hold. …
Merck & Co. (MRK) announced late Friday that it withdrew its application for approval of Keytruda in Europe. Merck gapped open lower Monday morning and is now down 2.83 at $55.41. The stock has been pulling back from resistance at the …
3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 …